Global Polymyalgia Rheumatica Treatment Market Research Report 2021-2026 Featuring Sanofi, Apotex, GlaxoSmithKline, AbbVie, & Horizon Therapeutic - ResearchAndMarkets.com

The "Global Polymyalgia Rheumatica Treatment Market Report and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Global polymyalgia rheumatica market attained a value of about USD 177 million in 2020. Aided by the rising prevalence of GCA with the rapid spread of COVID-19, the market is projected to further grow at a CAGR of 4.8% between 2021 and 2026 to reach a value of USD 233 million by 2026.

Polymyalgia rheumatica is a common condition that causes stiffness and pain in the muscles in the neck, shoulders, hips, and thighs. Apart from pain and stiffness, this condition is accompanied by flu-like symptoms. It mostly affects people above the age of 50 and commonly occurs among women.

In addition, people suffering from polymyalgia rheumatica are at greater risk of getting the disease called giant cell arteritis, which involves inflammation of the blood vessels, mainly in the temporal arteries. GCA, if not treated urgently, can lead to permanent vision loss.

Furthermore, polymyalgia rheumatica is an autoimmune disease with no known cause, although claims have been made suggesting a link between genetic and environmental factors causing the spread of this condition.

The global polymyalgia rheumatica market is being driven by the heightened adoption of advanced diagnostic technology worldwide. The rising number of studies and research on polymyalgia rheumatic concerning musculoskeletal symptoms are expected to drive the market growth.

In addition, the implementation of advanced diagnostic technologies to analyse subacromial and subdeltoid bursitis of shoulders, hip synovitis, and iliopectineal bursitis to develop efficient treatment is predicted to propel the industry growth.

The rapid technological advancements in technologies such as magnetic resonance imaging (MRI) are helping to decrease the chances of errors and contributing to a swift and effective diagnosis of the disease. The physical therapy is gaining prominence among consumers, as it is extremely effective with no side effects.

Physiotherapies are personalised treatments based on the severity of the condition that helps to reduce the stiffness in the muscles and improve muscle strength. Thus, the factors are estimated to significantly impact the market growth in the forecast period.

Market Segmentation

The market report analyses the market based on segmentation such as diagnostic method, drug class, route of administration, end-use and major regions.

Market Breakup by Diagnostic Method

• Blood Tests
• Imaging Tests

Market Segmentation by Drug Class

• Corticosteroids
• Disease-Modifying Anti-Rheumatic Drugs
• Non-Steroidal Anti-Inflammatory Drugs
• Others

Market Distribution by Route of Administration:

• Oral
• Parenteral

Market Division by End Use:

• Hospitals
• Homecare
• Speciality Clinics
• Others

Market Breakup by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the key players in the industry.

Some of the major players in the market explored in the report are:

• Sanofi SA
• Apotex Corporation
• GlaxoSmithKline plc
• AbbVie Inc.
• Horizon Therapeutics plc

For more information about this report visit https://www.researchandmarkets.com/r/rvrfm9

View source version on businesswire.com: https://www.businesswire.com/news/home/20210813005197/en/